Search

Your search keyword '"Yassin, Aksam"' showing total 437 results
Start Over Author "Yassin, Aksam"
437 results on '"Yassin, Aksam"'

9. Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope

Author

Al-Omari, Mothana K., primary, Elaarag, Mai, additional, Al-Zoubi, Raed M., additional, Al-Qudimat, Ahmad R., additional, Zarour, Ayman A., additional, Al-Hurani, Enas A., additional, Fares, Zainab E., additional, Alkharraz, Leena M., additional, Shkoor, Mohanad, additional, Bani-Yaseen, Abdulilah D., additional, Aboumarzouk, Omar M., additional, Yassin, Aksam, additional, and Al-Ansari, Abdulla A., additional

Published
2023
Full Text
View/download PDF

14. Efficacy and Clinical Outcomes of mRNA COVID-19 Vaccine in Pregnancy: A Systematic Review and Meta-Analysis

Author

Santimano, Antonio J., Al-Zoubi, Raed M., Al-Qudimat, Ahmad R., Al Darwish, Mohamed B., Ojha, Laxmi Kumari, Rejeb, Mohamed Amine, Hamad, Yasser, Elrashid, Malaz A., Ruxshan, Noorah M., El Omri, Abdelfatteh, Bawadi, Hiba, Al-Asmakh, Maha A., Yassin, Aksam, Aboumarzouk, Omar M., Zarour, Ahmad, and Al-Ansari, Abdulla A.

Abstract

Background:The world has witnessed one of the largest pandemics, dubbed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, the USA alone reported 98,948 cases of coronavirus disease 2019 (COVID-19) infection during pregnancy, with 109 related maternal deaths. Current evidence suggests that unvaccinated pregnant women infected with SARS-CoV-2 are at a higher risk of experiencing complications related to COVID-19 compared to nonpregnant women. This review aimed to provide healthcare workers and non-healthcare workers with a comprehensive overview of the available information regarding the efficacy of vaccines in pregnant women. Summary:We performed a systematic review and meta-analysis following PRISMA guidelines. The search through the database for articles published between December 2019 and October 2021 was performed. A comprehensive search was performed in PubMed, Scopus, and EMBASE databases for research publications published between December 2019 and October 2021. We focused on original research, case reports, case series, and vaccination side effect by authoritative health institutions. Phrases used for the Medical Subject Heading [MeSH] search included (“COVID-19” [MeSH]) or (“Vaccine” [MeSH]) and (“mRNA” [MeSH]) and (“Pregnant” [MeSH]). Eleven studies were selected and included, with a total of 46,264 pregnancies that were vaccinated with mRNA-containing lipid nanoparticle vaccine from Pfizer/BioNTech and Moderna during pregnancy. There were no randomized trials, and all studies were observational (prospective, retrospective, and cross-sectional). The mean maternal age was 32.2 years, and 98.7% of pregnant women received the Pfizer COVID-19 vaccination. The local and systemic adverse effects of the vaccination in pregnant women were analyzed and reported. The local adverse effects of the vaccination (at least 1 dose) such as local pain, swelling, and redness were reported in 32%, 5%, and 1%, respectively. The systemic adverse effects such as fatigue, headaches, new onset or worsening of muscle pain, chills, fever, and joint pains were also reported in 25%, 19%, 18%, 12%, 11%, and 8%, respectively. The average birthweight was 3,452 g. Among these pregnancies, 0.03% were stillbirth and 3.68% preterm (37 weeks) births. Key Messages:The systemic side effect profile after administering the COVID-19 mRNA vaccine to pregnant women was similar to that in nonpregnant women. Maternal and fetal morbidity and mortality were lowered with the administration of either one or both the doses of the mRNA COVID-19 vaccination.

Published
2023
Full Text
View/download PDF

17. COVID‐19 effect on patients with noncommunicable diseases: A narrative review

Author

Al‐Qudimat, Ahmad R., primary, Al Darwish, Mohamed B., additional, Elaarag, Mai, additional, Al‐Zoubi, Raed M., additional, Rejeb, Mohamed Amine, additional, Ojha, Laxmi K., additional, Nashwan, Abdulqadir J., additional, Alshunag, Timoor, additional, Adawi, Karam, additional, Omri, Abdelfettah El, additional, Aboumarzouk, Omar M., additional, Yassin, Aksam, additional, and Al‐Ansari, Abdulla A., additional

Published
2022
Full Text
View/download PDF

20. Testosterone and Covid‐19: An update

Author

Yassin, Aksam, primary, Sabsigh, Ridwan, additional, Al‐Zoubi, Raed M., additional, Aboumarzouk, Omar M., additional, Alwani, Mustafa, additional, Nettleship, Joanne, additional, and Kelly, Daniel, additional

Published
2022
Full Text
View/download PDF

23. The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study

Author

Yassin, Aksam, Saad, Farid, Alwani, Mustafa, Aboumarzouk, Omar M, Al-Zoubi, Raed M, Nettleship, Joanne, Kelly, Daniel, and Al-Ansari, Abdulla

Subjects
Male, Estradiol, Hypogonadism, Endocrine System, Luteinizing Hormone, Prolactin, Sex Hormone-Binding Globulin, Humans, Testosterone, Prospective Studies, Registries, Geriatrics and Gerontology, Follicle Stimulating Hormone, Progesterone
Abstract

Testosterone therapy (TTh) is the primary treatment for aging men with functional hypogonadism. Whilst the benefits of testosterone (T) replacement are well-evidenced, the long-term data for TTh on metabolic and endocrine parameters is limited. Here we present the effect of TTh on endocrine parameters in hypogonadal men at a 12-year follow-up. In this single-centre, cumulative, prospective, registry study, 321 hypogonadal men (mean age: 58.9 years) received testosterone undecanoate injections in 12-week intervals for up to 12 years. Blood samples were taken at every other visit to measure levels of total T (TT), calculated free T, sex hormone-binding globulin (SHBG), estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), progesterone and prolactin. We observed an increase in TT of 15.5 nmol/L (p p p p p p p

Published
2022

30. Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study)

Author

Buvat, Jacques, Montorsi, Francesco, Maggi, Mario, Porst, Hartmut, Kaipia, Antti, Colson, Marie Helène, Cuzin, Beatrice, Moncada, Ignacio, Martin‐Morales, Antonio, Yassin, Aksam, Meuleman, Eric, Eardley, Ian, Dean, John Daniel, and Shabsigh, Ridwan

Published
2011
Full Text
View/download PDF

35. COVID‐19 effect on patients with noncommunicable diseases: A narrative review.

Author

Al‐Qudimat, Ahmad R., Al Darwish, Mohamed B., Elaarag, Mai, Al‐Zoubi, Raed M., Rejeb, Mohamed Amine, Ojha, Laxmi K., Nashwan, Abdulqadir J., Alshunag, Timoor, Adawi, Karam, Omri, Abdelfettah El, Aboumarzouk, Omar M., Yassin, Aksam, and Al‐Ansari, Abdulla A.

Subjects
NON-communicable diseases, COVID-19 pandemic, COVID-19, MEDICAL personnel, DISEASE management
Abstract

Background and Aims: On March 11, 2020, the WHO has declared COVID‐19 a global pandemic, affecting our day‐to‐day lives. Physical distancing and lockdown made significant obstacles to populations, particularly healthcare systems. Most healthcare workers were reallocated to COVID‐19 facilities. Noncommunicable disease patients were given low priority and are at a higher risk of severe COVID‐19 infection, which disrupted the treatment and disease management of these patients. This review aimed to assess the effect of COVID‐19 on different types of noncommunicable diseases and the severity it may cause to patients. Methods: We have conducted a review of the literature on COVID‐19 and noncommunicable diseases from December 2019 until January 2022. The search was done in PubMed and Cochrane for relevant articles using variety of searching terms. Data for study variables were extracted. At the end of the selection process, 46 papers were selected for inclusion in the literature review. Result: The result from this review found that the COVID‐19 pandemic has affected the efficiency of the patient's treatment indirectly by either delaying or canceling sessions, which solidified the need to rely more on telemedicine, virtual visits, and in‐home visits to improve patient education and minimize the risk of exposure to the patients. The major and most common types of noncommunicable diseases are known to be related to the severe outcomes of COVID‐19 infection. It is strongly recommended to prioritize these patients for vaccinations against COVID‐19 to provide them with the protection that will neutralize the risk imposed by their comorbidities. Conclusion: We recommend conducting more studies with larger population samples to further understand the role of noncommunicable diseases (NCDs) in this pandemic. However, this pandemic has also affected the efficiency of NCDs treatment indirectly by delaying or canceling sessions and others. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Testosterone and Covid‐19: An update.

Author

Yassin, Aksam, Sabsigh, Ridwan, Al‐Zoubi, Raed M., Aboumarzouk, Omar M., Alwani, Mustafa, Nettleship, Joanne, and Kelly, Daniel

Abstract

There is overwhelming evidence to suggest that male gender is at a higher risk of developing more severe Covid‐19 disease and thus having poorer clinical outcomes. However, the relationship between testosterone (T) and Covid‐19 remains unclear with both protective and deleterious effects on different aspects of the disease suggested. Here, we review the current epidemiological and biological evidence on the role of testosterone in the process of SARS‐CoV‐2 infection and in mediating Covid‐19 severity, its potential to serve as a biomarker for risk stratification and discuss the possibility of T supplementation as a treatment or preventative therapy for Covid‐19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data

Author

Alwani, Mustafa, primary, Yassin, Aksam, additional, Talib, Raidh, additional, Al-Qudimat, Ahmad, additional, Aboumarzouk, Omar, additional, Al-Zoubi, Raed M, additional, Saad, Farid, additional, Haider, Karim S, additional, and Al Ansari, Abdulla, additional

Published
2021
Full Text
View/download PDF

45. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data

Author

Alwani,Mustafa, Yassin,Aksam, Talib,Raidh, Al-Qudimat,Ahmad, Aboumarzouk,Omar, Al-Zoubi,Raed M, Saad,Farid, Haider,Karim S, Al Ansari,Abdulla, Alwani,Mustafa, Yassin,Aksam, Talib,Raidh, Al-Qudimat,Ahmad, Aboumarzouk,Omar, Al-Zoubi,Raed M, Saad,Farid, Haider,Karim S, and Al Ansari,Abdulla

Abstract

Mustafa Alwani,1,2 Aksam Yassin,2– 4 Raidh Talib,2 Ahmad Al-Qudimat,2 Omar Aboumarzouk,2 Raed M Al-Zoubi,2,5 Farid Saad,6 Karim S Haider,7 Abdulla Al Ansari2 1Jordan University of Science and Technology, School of Medicine, Irbid, Jordan; 2Hamad Medical Corporation, Department of Surgery, Division of Urology/Andrology and Section of Surgical Research, Doha, Qatar; 3Weill Cornell Medical College, New York, NY, USA; 4Weill Cornell Medical College, Doha, Qatar; 5Jordan University of Science and Technology, Department of Chemistry, Irbid, Jordan; 6Dresden International University, Center of Medicine and Health Sciences, Dresden, Germany; 7Klinikum Bremen-Mitte, Department of Urology, Bremen, GermanyCorrespondence: Aksam Yassin Rathausallee 94 A, Norderstedt-Hamburg, 22846, GermanyTel +49 40 526 21 57Fax +49 40 526 28 20Email yassin@t-online.dePurpose: Erectile dysfunction (ED) is associated with testosterone deficiency and is a symptom of functional hypogonadism. A correlation between ED and cardiovascular disease (CVD) has been recognized, and ED has been proposed as an early marker of CVD. However, the relationship between ED and CVD risk in hypogonadism requires clarification and whether testosterone therapy (TTh) can be a beneficial treatment strategy, but long-term data are limited. This study investigates long-term TTh in men with hypogonadism and ED with a history of CVD.Methods: Seventy-seven patients with a history of CVD and diagnosed with functional hypogonadism and erectile dysfunction (erectile function domain score < 21 on the International Index of Erectile Function questionnaire (IIEF questions 1– 5)) were enrolled and TTh effects on anthropometric and metabolic parameters investigated for a maximum duration of 12 years. All men received long-acting injections of testosterone undecanoate at 3-monthly intervals. Eight-year data were analysed. Data collection registry started in November 2004 till January 2015.Results: In hypogonadal men receiving T

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results